Business Description
Evotec SE
ISIN : DE0005664809
Compare
Compare
Traded in other countries / regions
EVT.Germany0IRF.UKEVO.USA1EVT.ItalyEVT.BulgariaEVT.Austria IPO Date
2023-11-13Description
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.83 | |||||
Equity-to-Asset | 0.5 | |||||
Debt-to-Equity | 0.57 | |||||
Debt-to-EBITDA | -7.03 | |||||
Piotroski F-Score | N/A/9 | |||||
Altman Z-Score | 0.97 | |||||
WACC vs ROIC |
Growth Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 10.7 | |||||
3-Year EBITDA Growth Rate | -38.6 | |||||
3-Year FCF Growth Rate | -42.2 | |||||
3-Year Book Growth Rate | 12.6 | |||||
Future 3-5Y Total Revenue Growth Rate | 15.28 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 30.5 | |||||
9-Day RSI | 43.71 | |||||
14-Day RSI | 46.43 | |||||
6-1 Month Momentum % | -50.35 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.86 | |||||
Quick Ratio | 1.79 | |||||
Cash Ratio | 1.17 | |||||
Days Inventory | 18.73 | |||||
Days Sales Outstanding | 64.71 | |||||
Days Payable | 64.21 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.7 | |||||
Shareholder Yield % | -7.65 |
Profitability Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 20.16 | |||||
Operating Margin % | -10.09 | |||||
Net Margin % | -11.68 | |||||
FCF Margin % | -28.9 | |||||
ROE % | -7.99 | |||||
ROA % | -4.02 | |||||
ROIC % | -4.2 | |||||
ROC (Joel Greenblatt) % | -11.45 | |||||
ROCE % | -4.97 | |||||
Years of Profitability over Past 10-Year | 7 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 192.31 | |||||
Shiller PE Ratio | 61.01 | |||||
PS Ratio | 2.02 | |||||
PB Ratio | 1.42 | |||||
Price-to-Tangible-Book | 1.94 | |||||
EV-to-EBIT | -18.83 | |||||
EV-to-Forward-EBIT | 68.56 | |||||
EV-to-EBITDA | -18.83 | |||||
EV-to-Forward-EBITDA | 14.27 | |||||
EV-to-Revenue | 2.16 | |||||
EV-to-Forward-Revenue | 1.84 | |||||
EV-to-FCF | -7.49 | |||||
Price-to-Projected-FCF | 2.71 | |||||
Price-to-Median-PS-Value | 0.3 | |||||
Earnings Yield (Greenblatt) % | -5.31 | |||||
FCF Yield % | -14.28 | |||||
Forward Rate of Return (Yacktman) % | 23.21 |